ECSP19030134A - Compuesto de piridina - Google Patents

Compuesto de piridina

Info

Publication number
ECSP19030134A
ECSP19030134A ECSENADI201930134A ECDI201930134A ECSP19030134A EC SP19030134 A ECSP19030134 A EC SP19030134A EC SENADI201930134 A ECSENADI201930134 A EC SENADI201930134A EC DI201930134 A ECDI201930134 A EC DI201930134A EC SP19030134 A ECSP19030134 A EC SP19030134A
Authority
EC
Ecuador
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
compound
formula
Prior art date
Application number
ECSENADI201930134A
Other languages
English (en)
Inventor
Yasuyuki Kaneta
Yoshihiro Shibata
Hiroaki Inagaki
Hidenori Namiki
Kiyoshi Nakayama
Hideaki Kageji
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of ECSP19030134A publication Critical patent/ECSP19030134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención tiene relación con un compuesto que tiene acción inhibidora de quinasa RET o una sal farmacéuticamente aceptable del mismo, útil en el tratamiento de enfermedades como cáncer. En particular un compuesto representado por la siguiente fórmula general (I) como se define en este documento: [Fórmula I] (ver figura) o una sal farmacéuticamente aceptable del mismo.
ECSENADI201930134A 2016-09-29 2019-04-29 Compuesto de piridina ECSP19030134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (en) 2016-09-29 2017-09-28 Pyridine compound

Publications (1)

Publication Number Publication Date
ECSP19030134A true ECSP19030134A (es) 2019-08-30

Family

ID=60020249

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201930134A ECSP19030134A (es) 2016-09-29 2019-04-29 Compuesto de piridina

Country Status (33)

Country Link
US (2) US10851092B2 (es)
EP (2) EP3519398B1 (es)
JP (2) JP2018052878A (es)
KR (1) KR102520543B1 (es)
CN (2) CN113788824A (es)
AU (2) AU2017335242C1 (es)
BR (1) BR112019006047A2 (es)
CA (1) CA3035860A1 (es)
CL (1) CL2019000844A1 (es)
CO (1) CO2019004034A2 (es)
CY (1) CY1123988T1 (es)
DK (1) DK3519398T3 (es)
EA (1) EA037103B1 (es)
EC (1) ECSP19030134A (es)
ES (1) ES2868748T3 (es)
HR (1) HRP20210447T1 (es)
HU (1) HUE054824T2 (es)
IL (1) IL265630B (es)
LT (1) LT3519398T (es)
MA (2) MA46337B1 (es)
MD (1) MD3519398T2 (es)
MX (1) MX2019003747A (es)
PE (1) PE20190805A1 (es)
PH (1) PH12019500480A1 (es)
PL (1) PL3519398T3 (es)
PT (1) PT3519398T (es)
RS (1) RS61640B1 (es)
SG (1) SG11201901937WA (es)
SI (1) SI3519398T1 (es)
SM (1) SMT202100315T1 (es)
UA (1) UA123964C2 (es)
WO (1) WO2018060714A1 (es)
ZA (1) ZA201902232B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3371171T1 (sl) 2015-11-02 2024-03-29 Blueprint Medicines Corporation Inhibitorji ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
PE20210096A1 (es) 2018-04-03 2021-01-12 Blueprint Medicines Corp Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP7642556B2 (ja) * 2019-11-18 2025-03-10 中外製薬株式会社 併用医薬
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021164741A1 (zh) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 苯基双酰胺类化合物
US12565481B2 (en) 2020-02-20 2026-03-03 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory 6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib
WO2022238706A1 (en) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
MX2024004848A (es) 2021-10-22 2024-07-15 Univ Houston System Metodos y composiciones para el tratamiento de lesiones inflamatorias cronicas, metaplasias, displasia y canceres de tejidos epiteliales.
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2007099323A2 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
EP1994023A1 (en) 2006-03-02 2008-11-26 AstraZeneca AB Quinazoline derivatives
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
WO2007113548A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
SG173884A1 (en) * 2009-02-27 2011-10-28 Teijin Pharma Ltd Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
EP3103452A1 (en) 2009-08-25 2016-12-14 Abraxis BioScience, LLC Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
CN102946881A (zh) 2010-04-23 2013-02-27 奇尼塔公司 抗病毒化合物
JP6097998B2 (ja) 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
SMT201700152T1 (it) * 2013-03-15 2017-05-08 Glaxosmithkline Ip Dev Ltd Derivati piridinici come inibitori della chinasi riarrangiata durante la trasfezione (ret)
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9783522B2 (en) * 2014-04-24 2017-10-10 Mitsubishi Tanabe Pharma Corporation 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
WO2016038552A1 (en) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
WO2016037578A1 (en) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Novel compounds as rearranged during transfection (ret) inhibitors
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
WO2016127074A1 (en) * 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
ZA201902232B (en) 2022-12-21
PT3519398T (pt) 2021-03-24
US20210163464A1 (en) 2021-06-03
KR20190086442A (ko) 2019-07-22
WO2018060714A1 (en) 2018-04-05
DK3519398T3 (da) 2021-03-29
CL2019000844A1 (es) 2019-06-07
HRP20210447T1 (hr) 2021-07-23
US20200039974A1 (en) 2020-02-06
HUE054824T2 (hu) 2021-10-28
IL265630A (en) 2019-05-30
EA201990833A1 (ru) 2019-10-31
PE20190805A1 (es) 2019-06-10
MA46337A (fr) 2019-08-07
CN110036007A (zh) 2019-07-19
LT3519398T (lt) 2021-05-10
AU2017335242B2 (en) 2021-08-19
MA46337B1 (fr) 2021-04-30
CN113788824A (zh) 2021-12-14
PH12019500480A1 (en) 2019-08-05
RS61640B1 (sr) 2021-04-29
KR102520543B1 (ko) 2023-04-10
EA037103B1 (ru) 2021-02-05
AU2017335242A1 (en) 2019-05-02
AU2021261899A1 (en) 2021-12-02
BR112019006047A2 (pt) 2019-06-25
ES2868748T3 (es) 2021-10-21
MX2019003747A (es) 2019-09-19
PL3519398T3 (pl) 2021-06-28
MD3519398T2 (ro) 2021-05-31
EP3519398B1 (en) 2021-02-24
AU2017335242C1 (en) 2021-12-09
JP2019534871A (ja) 2019-12-05
SMT202100315T1 (it) 2021-07-12
IL265630B (en) 2021-10-31
EP3519398A1 (en) 2019-08-07
SI3519398T1 (sl) 2021-07-30
EP3828178A1 (en) 2021-06-02
JP2018052878A (ja) 2018-04-05
CO2019004034A2 (es) 2019-07-10
US10851092B2 (en) 2020-12-01
CN110036007B (zh) 2021-10-15
JP7098609B2 (ja) 2022-07-11
CA3035860A1 (en) 2018-04-05
SG11201901937WA (en) 2019-04-29
UA123964C2 (uk) 2021-06-30
CY1123988T1 (el) 2022-05-27
MA54910A (fr) 2022-04-13

Similar Documents

Publication Publication Date Title
ECSP19030134A (es) Compuesto de piridina
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
DOP2020000112A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
ECSP20035588A (es) Derivado de amino-metil piperidina como inhibidor de quinasa
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
PE20151654A1 (es) Inhibidores de cdc7
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
MX2017015277A (es) Derivado de pirido[3,4-d]pirimidina y sal farmaceuticamente aceptable de este.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
CU20160195A7 (es) Derivados de quinolizinona como inhibidores de pi3k
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
UY35317A (es) Compuesto de ciclopropanoamina